A federal judge ruled in favor of Merck in litigation accusing it of concealing the risks of Gardasil, a vaccine to prevent cervical and other cancers caused by the human papillomavirus and one of the ...

A federal judge has ruled in favor of Merck in litigation accusing the drugmaker of concealing the risks of Gardasil, a vaccine to prevent cervical and other fatal cancers. The decision made public on ...

NEW YORK, NY / ACCESS Newswire / March 27, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn ...

Despite this potential, the stock has fallen by 25% in the past 12 months -- so is it a bargain buy right now? During the ...

Within that group, biotechnology giant Amgen (NASDAQ: AMGN) has been the best-performing stock in 2025, returning an ...

Merck's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028. See why I rate MRK stock a hold.

Merck & Co. (MRK) releases positive phase three data for its injectable-form cancer drug Keytruda. Yahoo Finance Senior ...

When topline phase III data was released in November, hinting at the potential of success, Jefferies analyst Akash Tiwari ...

NEW YORK, NY / ACCESS Newswire / March 25, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Merck & Co., Inc. (NYSE:MRK) between February 3, 2022 and ...

On July 30, 2024, Merck released its second quarter 2024 financial report and disclosed a significant reduction in Gardasil vaccinations, resulting in an overabundance of inventory at Merck’s ...

Rising competitive pressure on the diabetes franchise and persistent challenges for its human papillomavirus vaccine, Gardasil in China remain overhangs. There are concerns about Merck’s ability ...